Key points are not available for this paper at this time.
Renal cell carcinoma (RCC) evolves within a chronic inflammatory renal niche, where angiogenesis, metabolism, and immune programs synergize to reshape the tumor immune microenvironment (TIME). Recurrent renal damage and tissue hypoxia sustain NF-κB/STAT3 and HIF-VEGF signaling, while a sustained IFN-γ response enhances antigen presentation while inducing inhibitory checkpoints, promoting a state of “inflammation but constrained.” Single-cell and spatial studies reveal early microenvironment heterogeneity and the chemokine-checkpoint paradox: regions enriched in CXCL9/10 coexist with endothelial inertia, cancer-associated fibroblasts (CAFs)-mediated stromal barriers, and metabolic stress, which collectively exclude functional CD8 + T cells. In advanced clear cell RCC, immuno-inflammatory, immuno-excluded, and immuno-desert phenotypes often coexist and undergo transitions during treatment, leading to heterogeneity in response to immune checkpoint blockade (ICB). We propose a modular perspective-the NF-κB/STAT3, HIF-VEGF, IFN-γ circuits and auxiliary regulatory factors-to link stage-specific biology with treatment matching. Integrative biomarkers couple IFN-γ characteristics with angiogenesis/stromal modules and spatial indicators, offering superior predictive power compared to single tests. These insights support the adoption of a combined strategy: integrating vascular normalization or stromal/myeloid cell reprogramming on the basis of ICB, and encouraging the use of longitudinal “immune snapshots” to guide intervention and precision immunotherapy for renal cancer.
Xu et al. (Tue,) studied this question.